Amyl Therapeutics

📍 Liège, Belgium🗓 Founded 2020👥 12 employees💰 Last funded 2023
Biotechnology Research🌐 amyltx.com
Website LinkedIn
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by neurodegenerative diseases such as Alzheimers and Parkinsons diseases, or by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
France
1
Frequently asked questions
Who invested in Amyl Therapeutics?
Amyl Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Amyl Therapeutics last raise funding?
The most recent investment in Amyl Therapeutics recorded on gritt.io was in 2023.
When was Amyl Therapeutics founded?
Amyl Therapeutics was founded in 2020.
What industry is Amyl Therapeutics in?
Amyl Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Amyl Therapeutics based?
Amyl Therapeutics is headquartered in Liège, Belgium.